AtriCure (NASDAQ:ATRC)‘s stock had its “hold” rating reaffirmed by stock analysts at BTIG Research in a report released on Wednesday.
Several other equities research analysts also recently commented on the stock. Canaccord Genuity restated a “buy” rating and issued a $35.00 price target (up previously from $27.00) on shares of AtriCure in a research report on Wednesday. Stifel Nicolaus upped their price target on shares of AtriCure from $23.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday. Zacks Investment Research downgraded shares of AtriCure from a “hold” rating to a “sell” rating in a research report on Tuesday. Piper Jaffray Companies upped their price target on shares of AtriCure to $30.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Needham & Company LLC upped their price target on shares of AtriCure from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, June 18th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $30.80.
Shares of NASDAQ:ATRC opened at $27.99 on Wednesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.15 and a quick ratio of 2.31. The company has a market capitalization of $945.03 million, a P/E ratio of -33.72 and a beta of 0.24. AtriCure has a 52 week low of $14.88 and a 52 week high of $30.96.
AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Thursday, April 26th. The medical device company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.04). The firm had revenue of $46.99 million during the quarter, compared to analysts’ expectations of $45.43 million. AtriCure had a negative net margin of 14.88% and a negative return on equity of 16.92%. The firm’s revenue was up 13.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.32) EPS. research analysts expect that AtriCure will post -0.86 earnings per share for the current year.
In other AtriCure news, Director Mark A. Collar sold 2,090 shares of the stock in a transaction that occurred on Thursday, June 14th. The shares were sold at an average price of $25.00, for a total value of $52,250.00. Following the completion of the sale, the director now owns 66,898 shares in the company, valued at approximately $1,672,450. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Elizabeth D. Krell sold 10,000 shares of the stock in a transaction that occurred on Tuesday, May 8th. The stock was sold at an average price of $22.82, for a total transaction of $228,200.00. Following the completion of the sale, the director now owns 29,967 shares of the company’s stock, valued at approximately $683,846.94. The disclosure for this sale can be found here. 8.70% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the business. Highbridge Capital Management LLC purchased a new stake in AtriCure in the 1st quarter worth approximately $208,000. Trexquant Investment LP purchased a new stake in AtriCure in the 1st quarter worth approximately $224,000. Teacher Retirement System of Texas purchased a new stake in AtriCure in the 4th quarter worth approximately $203,000. HBK Investments L P purchased a new stake in AtriCure in the 4th quarter worth approximately $255,000. Finally, JPMorgan Chase & Co. lifted its position in AtriCure by 105.1% in the 1st quarter. JPMorgan Chase & Co. now owns 14,208 shares of the medical device company’s stock worth $292,000 after buying an additional 7,281 shares in the last quarter. Institutional investors own 87.52% of the company’s stock.
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.